SCHEDULE: Fuller & Thaler Discloses 5.1% Stake in Indivior

Fuller & Thaler Asset Management, Inc. has reported a passive 5.10% ownership stake in Indivior Pharmaceuticals, Inc. as of December 31, 2025.

Summary

• Fuller & Thaler Asset Management, Inc. beneficially owns 6,371,533.70 shares of Indivior Pharmaceuticals, Inc. Common Stock.
• This ownership represents 5.10% of the class of securities.
• Fuller & Thaler Asset Management, Inc. holds sole voting power over 6,193,613.70 shares and sole dispositive power over all 6,371,533.70 shares.
• The filing is a Schedule 13G, indicating passive investment intent, not for the purpose of changing or influencing control of the issuer.
• Fuller & Thaler acts as an investment adviser to certain persons, and these persons have the right to receive dividends or proceeds from the sale of the Common Stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development for Indivior, as it confirms significant institutional interest and a passive investment approach, which typically implies long-term holding.

Positives

• The disclosure of a 5.10% stake by Fuller & Thaler Asset Management, Inc. indicates significant institutional interest and confidence in Indivior Pharmaceuticals, Inc.

Industry Context

StockSavvy.ai notes that the disclosure of a significant passive stake by an investment adviser like Fuller & Thaler Asset Management is a routine but important transparency event in the financial markets. It signals that a notable institutional investor sees value in Indivior Pharmaceuticals, Inc. as part of its client portfolios, aligning with broader trends of institutional capital allocation in the pharmaceutical sector.

Stakeholder Impact

• Shareholders of Indivior Pharmaceuticals, Inc. benefit from increased transparency regarding significant institutional ownership, which can contribute to market confidence.
• Fuller & Thaler Asset Management, Inc.'s clients are the ultimate beneficial owners, with rights to dividends and proceeds from the sale of securities.

Key Dates

Recommendation

A 'hold' recommendation is appropriate as the filing indicates a significant, passive institutional investment in Indivior Pharmaceuticals, Inc. by Fuller & Thaler Asset Management. While this signals institutional confidence and can be a positive indicator, the Schedule 13G itself does not provide operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It primarily confirms a substantial, non-controlling stake, suggesting stability in institutional ownership.

Keywords

Indivior Pharmaceuticals, Fuller & Thaler Asset Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Passive Investment